A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

NCT07630974 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

134

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Neoplasm

Interventions

BIOLOGICAL: Ifinatamab Deruxtecan

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]